Clinical Studies
OAK
OAK: the largest Phase III cancer immunotherapy study in previously treated advanced NSCLC, regardless of PD-L1 expression1
Mechanism of Action
References:
1. TECENTRIQ prescribing information.
MatCode Approval No.: -1905-V2-3253